Prescription medicine
Voriconazole Brand names: Vfend
Voriconazole (Vfend) is a prescription medicine with an FDA approval on record since 2002. FDA's NDC Directory lists it from 31 generic labelers, and pharmacies paid $1.88 per voriconazole 200 mg tablet in the October 7, 2026 NADAC survey.
- Generic listed
- A presentation discontinued
Check it at the source: the voriconazole FDA label on DailyMed (effective February 26, 2026, Roerig); the NDA 21266 record on Drugs@FDA; every voriconazole label on DailyMed.
Highlights of the record
FDA label of February 26, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageVFEND is an azole antifungal indicated for the treatment of adults and pediatric patients 2 years of age and older with:
Invasive aspergillosis ( 1.1 )
Candidemia in non-neutropenics and other deep tissue Candida infections ( 1.2 )
Esophageal candidiasis ( 1.3 )
Serious fungal infections caused by Scedosporium apiospermum and Fusarium species including Fusarium solani, in patients intolerant of, or refractory
Forms and strengths
- 50 mg
- 200 mg
- 10 mg/ml
- 40 mg/ml
Film-coated tablet; injection (powder) (lyophilized) for solution; powder for suspension; coated tablet; suspension.
On the market
- Earliest approval on file
- May 24, 2002 Vfend, Pf Prism Cv; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 28 first April 22, 2010; 23 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 33 of which 31 under generic applications, 2 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- $1.88 per tablet Voriconazole 200 mg tablet
- Shortage (FDA)
- None current 1 past records
- Recalls by its makers (FDA)
- 4 since 2013 0 Class I among all firms' recalls; latest March 24, 2025; 6 more by firms not listed as its makers
- FAERS reports
- 30,201 through July 30, 2026
What is voriconazole used for?
From the label: indications and usageVFEND is an azole antifungal indicated for the treatment of adults and pediatric patients 2 years of age and older with:
Invasive aspergillosis ( 1.1 )
Candidemia in non-neutropenics and other deep tissue Candida infections ( 1.2 )
Esophageal candidiasis ( 1.3 )
Serious fungal infections caused by Scedosporium apiospermum and Fusarium species including Fusarium solani, in patients intolerant of, or refractory to, other therapy ( 1.4 ) 1.1 Invasive Aspergillosis VFEND is indicated in adults and pediatric patients (2 years of age and older) for the treatment of invasive aspergillosis (IA). In clinical trials, the majority of isolates recovered were Aspergillus fumigatus. […]
Conditions named in the indications of voriconazole's FDA labels, with every medicine labeled for each:
FDA pharmacologic class: Azole Antifungal.
Source: FDA drug label (VFEND), NDA021630 (Pf Prism Cv), as published by Roerig, effective February 26, 2026 (SPL set ce3ef5cf-3087-4d92-9d94-9eb8287228db), via openFDA; the full label on DailyMed
What does the patient leaflet for voriconazole say first?
The FDA-approved Medication Guide or Patient Information that comes with the medicine, in its own words.
From the patient leaflet: What should I avoid while taking VFEND?You should not drive at night while taking VFEND. VFEND can cause changes in your vision such as blurring or sensitivity to light. • Do not drive or operate machinery, or do other dangerous activities until you know how VFEND affects you. • Avoid direct sunlight. VFEND can make your skin sensitive to the sun and the light from sunlamps and tanning beds. You could get a severe sunburn. Use sunscreen and wear a hat and clothes that cover your skin if you have to be in sunlight. Talk to your healthcare provider if you get sunburn.
From the patient leaflet: How should I store VFEND?Store VFEND tablets and oral suspension at room temperature between 59°F to 86°F (15°C to 30°C). Do not refrigerate or freeze. • VFEND oral suspension should be thrown away (discarded) after 14 days. • Keep VFEND tablets and oral suspension in a tightly closed container. • Safely throw away medicine that is out of date or no longer needed. • Keep VFEND, as well as all other medicines, out of the reach of children.
Source: FDA drug label (VFEND), NDA021630 (Pf Prism Cv), as published by Roerig, effective February 26, 2026 (SPL set ce3ef5cf-3087-4d92-9d94-9eb8287228db), via openFDA; the full label on DailyMed
Is there a generic for voriconazole (Vfend)?
The FDA approved the first generic voriconazole on April 22, 2010. 28 generic applications are approved; 23 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
FDA's NDC Directory lists voriconazole from 31 labelers under a generic (ANDA) application and from 2 brand labelers. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
- 2002 earliest approval on file
- 2010 first generic approved
- red ticks recalls
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for voriconazole (Vfend)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $1.88 per Voriconazole 200 mg tablet, down 2% from $1.92 on October 8, 2025. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Voriconazole 200 mg tablet (generic)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Voriconazole 200 mg tablet | Generic | $1.88 per tablet | $56.54 | -2% |
| Voriconazole 40 mg/mL suspension | Generic | $5.49 per mL | n/a | n/a |
| Voriconazole 50 mg tablet | Generic | $0.827 per tablet | $24.82 | +89% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
Is voriconazole in shortage?
No voriconazole presentation is listed as in shortage in the FDA Drug Shortage Database (read October 8, 2026); its 1 record is all marked to be discontinued, the latest updated October 16, 2025. ASHP keeps a separate shortage list, which can differ.
| Presentation | Company | Status | Updated |
|---|---|---|---|
| Vfend, Injection, 10 mg/1 mL (NDC 0049-3190-01) | Pfizer Inc. | To Be Discontinued | October 16, 2025 |
Every voriconazole presentation in the FDA shortage database
Source: FDA Drug Shortage Database via openFDA, updated October 8, 2026
Has voriconazole been recalled?
The FDA's Enforcement Report lists 10 recalls naming voriconazole since 2013: 0 Class I (the most serious), 9 Class II, 1 Class III; 2 still ongoing. 6 of them are by firms that FDA's NDC Directory does not list as a maker of voriconazole and that hold no application for it in Drugs@FDA, such as compounding pharmacies or bulk-ingredient suppliers; the recall notice names the product recalled. A recall names products and lots, not every product of the medicine.
| Started | Class | Company | Reason |
|---|---|---|---|
| March 24, 2025 | Class II | Amerisource Health Services LLC | cGMP Deviations: Received notification from their supplier requesting they perform a recall due to the fact they repackaged the product. |
| March 13, 2025 | Class II | Glenmark Pharmaceuticals Inc., USA | CGMP Deviations |
| February 5, 2024 | Class II | Lupin Pharmaceuticals Inc. | Labeling: Incorrect or Missing Package Insert |
| December 22, 2022 | Class II | Pharmacy Innovations not a listed maker | Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility. |
| July 19, 2017 | Class III | AVKARE Inc. not a listed maker | Failed impurities/degradation specifications: Out of specification for a related compound C. |
| September 12, 2015 | Class II | US Compounding Inc not a listed maker | Lack of Assurance of Sterility; The firm is recalling all sterile preparations that are within expiry due to deficient practices which may have an impact on … |
| August 27, 2014 | Class II | Martin Avenue Pharmacy, Inc. not a listed maker | Lack of Assurance of Sterility: Martin Avenue Pharmacy, Inc. is conducting a voluntary recall of all compounded sterile preparations within expiry. … |
| November 1, 2013 | Class II | Natures Pharmacy & Compounding Center not a listed maker | Lack of Sterility Assurance: All lots of sterile products compounded by the pharmacy that are not expired due to concerns associated with quality control … |
Source: FDA Enforcement Report (drug recalls) via openFDA, through October 8, 2026
What does the voriconazole label say about other medicines?
The voriconazole label names 56 other medicines in its interaction, contraindication or warning sections. The labels of 44 other medicines name voriconazole. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Alprazolam | drug interactions | Drug/Drug Class (Mechanism of Interaction by Voriconazole): Other benzodiazepines including triazolam and alprazolam (CYP3A4 Inhibition); Drug Plasma Exposure (C max and AUC τ): In Vitro Studies Demonstrated Potential for Voriconazole to Inhibit Metabolism (Increased Plasma Exposure); … |
| Axitinib | drug interactions | Drug/Drug Class (Mechanism of Interaction by Voriconazole): Tyrosine kinase inhibitors (including but not limited to axitinib, bosutinib, cabozantinib, ceritinib, cobimetinib, dabrafenib, dasatinib, nilotinib, sunitinib, ibrutinib, ribociclib) (CYP3A4 Inhibition); … |
| Bosutinib | drug interactions | Drug/Drug Class (Mechanism of Interaction by Voriconazole): Tyrosine kinase inhibitors (including but not limited to axitinib, bosutinib, cabozantinib, ceritinib, cobimetinib, dabrafenib, dasatinib, nilotinib, sunitinib, ibrutinib, ribociclib) (CYP3A4 Inhibition); … |
| Cabozantinib | drug interactions | Drug/Drug Class (Mechanism of Interaction by Voriconazole): Tyrosine kinase inhibitors (including but not limited to axitinib, bosutinib, cabozantinib, ceritinib, cobimetinib, dabrafenib, dasatinib, nilotinib, sunitinib, ibrutinib, ribociclib) (CYP3A4 Inhibition); … |
| Carbamazepine | contraindications | Carbamazepine |
| Ceritinib | drug interactions | Drug/Drug Class (Mechanism of Interaction by Voriconazole): Tyrosine kinase inhibitors (including but not limited to axitinib, bosutinib, cabozantinib, ceritinib, cobimetinib, dabrafenib, dasatinib, nilotinib, sunitinib, ibrutinib, ribociclib) (CYP3A4 Inhibition); … |
| Cobimetinib | drug interactions | Drug/Drug Class (Mechanism of Interaction by Voriconazole): Tyrosine kinase inhibitors (including but not limited to axitinib, bosutinib, cabozantinib, ceritinib, cobimetinib, dabrafenib, dasatinib, nilotinib, sunitinib, ibrutinib, ribociclib) (CYP3A4 Inhibition); … |
| Cyclosporine | drug interactions | Cyclosporine (CYP3A4 Inhibition) AUC τ Significantly Increased; |
| Dabrafenib | drug interactions | Drug/Drug Class (Mechanism of Interaction by Voriconazole): Tyrosine kinase inhibitors (including but not limited to axitinib, bosutinib, cabozantinib, ceritinib, cobimetinib, dabrafenib, dasatinib, nilotinib, sunitinib, ibrutinib, ribociclib) (CYP3A4 Inhibition); … |
| Dasatinib | drug interactions | Drug/Drug Class (Mechanism of Interaction by Voriconazole): Tyrosine kinase inhibitors (including but not limited to axitinib, bosutinib, cabozantinib, ceritinib, cobimetinib, dabrafenib, dasatinib, nilotinib, sunitinib, ibrutinib, ribociclib) (CYP3A4 Inhibition); … |
| Diclofenac | drug interactions | NSAIDs Non-Steroidal Anti-Inflammatory Drug including. ibuprofen and diclofenac (CYP2C9 Inhibition) Increased Frequent monitoring for adverse reactions and toxicity related to NSAIDs. |
| Dihydroergotamine | contraindications | Ergot alkaloids (e.g., ergotamine, dihydroergotamine) |
| Efavirenz | contraindications | Efavirenz Concomitant use with efavirenz dosages of 400 mg every 24 hours or higher is contraindicated [see Clinical Pharmacology (12.3) ]. |
| Eplerenone | drug interactions | Drug/Drug Class (Mechanism of Interaction by Voriconazole): Eplerenone (CYP3A4 Inhibition); Drug Plasma Exposure (C max and AUC τ): Not Studied In Vivo or In Vitro, but Voriconazole is Likely to Significantly Increase the Plasma Concentrations of Eplerenone; Prevention or Management Recommendations: Contraindicated |
Every other medicine the voriconazole label names
| Medicine named | Section | What the label says |
|---|---|---|
| Ergotamine | contraindications | Ergot alkaloids (e.g., ergotamine, dihydroergotamine) |
| Eszopiclone | drug interactions | Drug/Drug Class (Mechanism of Interaction by Voriconazole): Eszopiclone (CYP3A4 Inhibition); Drug Plasma Exposure (C max and AUC τ): Not Studied In Vivo or In Vitro, but Drug Plasma Exposure Likely … |
| Everolimus | drug interactions | Everolimus (CYP3A4 Inhibition) Not Studied In Vivo or In Vitro, but Drug Plasma Exposure Likely to be Increased Concomitant administration of voriconazole and everolimus is not recommended. |
| Fentanyl | drug interactions | Fentanyl (CYP3A4 Inhibition) Increased Reduction in the dose of fentanyl and other long-acting opiates metabolized by CYP3A4 should be considered when concomitantly administered with VFEND. |
| Finerenone | drug interactions | Drug/Drug Class (Mechanism of Interaction by Voriconazole): Finerenone (CYP3A4 Inhibition); Drug Plasma Exposure (C max and AUC τ): Not Studied In Vivo or In Vitro, but Voriconazole is Likely to … |
| Fluconazole | drug interactions | Fluconazole (CYP2C9, CYP2C19 and CYP3A4 Inhibition) Significantly Increased Avoid concomitant administration of voriconazole and fluconazole. |
| Glasdegib | drug interactions | Glasdegib (CYP3A4 Inhibition) Not Studied In Vivo or In Vitro, but Drug Plasma Exposure Likely to be Increased Consider alternative therapies. |
| Ibrutinib | drug interactions | … ceritinib, cobimetinib, dabrafenib, dasatinib, nilotinib, sunitinib, ibrutinib, ribociclib) (CYP3A4 Inhibition); Drug Plasma Exposure (C max and AUC τ): Not Studied In Vivo or In Vitro, but Drug … |
| Ibuprofen | drug interactions | NSAIDs Non-Steroidal Anti-Inflammatory Drug including. ibuprofen and diclofenac (CYP2C9 Inhibition) Increased Frequent monitoring for adverse reactions and toxicity related to NSAIDs. |
| Ivabradine | drug interactions | Drug/Drug Class (Mechanism of Interaction by Voriconazole): Pimozide, Quinidine, Ivabradine (CYP3A4 Inhibition); Drug Plasma Exposure (C max and AUC τ): Not Studied In Vivo or In Vitro, but Drug … |
| Ivacaftor | drug interactions | Drug/Drug Class (Mechanism of Interaction by Voriconazole): Ivacaftor (CYP3A4 Inhibition); Drug Plasma Exposure (C max and AUC τ): Not Studied In Vivo or In Vitro, but Drug Plasma Exposure Likely to … |
| Lemborexant | drug interactions | Lemborexant (CYP3A4 Inhibition) Not Studied In Vivo or In Vitro, but Drug Plasma Exposure Likely to be Increased Avoid concomitant use of VFEND with lemborexant. |
| Letermovir | drug interactions | Letermovir (CYP2C9/2C19 Induction) Reduced If concomitant administration of voriconazole with letermovir cannot be avoided, monitor for reduced effectiveness of voriconazole. |
| Lurasidone | drug interactions | Drug/Drug Class (Mechanism of Interaction by Voriconazole): Lurasidone (CYP3A4 Inhibition); Drug Plasma Exposure (C max and AUC τ): Not Studied In Vivo or In Vitro, but Voriconazole is Likely to … |
| Mavacamten | drug interactions | Drug/Drug Class (Mechanism of Interaction by Voriconazole): Mavacamten (CYP2C19/3A4/2C9 Inhibition); Drug Plasma Exposure (C max and AUC τ): Not Studied In Vivo or In Vitro, but Mavacamten Drug … |
| Methadone | drug interactions | Drug/Drug Class (Mechanism of Interaction by Voriconazole): Methadone Results based on in vivo clinical study following repeat oral dosing with 400 mg every 12 hours for 1 day, then 200 mg every 12 … |
| Methotrexate | warnings and precautions | … as well as increased risk of skin toxicity with concomitant use of methotrexate, a drug associated with ultraviolet (UV) reactivation. |
| Midazolam | drug interactions | Midazolam (CYP3A4 Inhibition) Significantly Increased Increased plasma exposures may increase the risk of adverse reactions and toxicities related to benzodiazepines. |
| Naloxegol | drug interactions | Drug/Drug Class (Mechanism of Interaction by Voriconazole): Naloxegol (CYP3A4 Inhibition); Drug Plasma Exposure (C max and AUC τ): Not Studied In Vivo or In Vitro, but Drug Plasma Exposure Likely to … |
| Nilotinib | drug interactions | … bosutinib, cabozantinib, ceritinib, cobimetinib, dabrafenib, dasatinib, nilotinib, sunitinib, ibrutinib, ribociclib) (CYP3A4 Inhibition); … |
| Norethindrone | drug interactions | Drug/Drug Class (Mechanism of Interaction by the Drug): Oral Contraceptives containing ethinyl estradiol and norethindrone (CYP2C19 Inhibition); … |
| Omeprazole | drug interactions | Drug/Drug Class (Mechanism of Interaction by Voriconazole): Omeprazole (CYP2C19/3A4 Inhibition); Drug Plasma Exposure (C max and AUC τ): Significantly Increased; … |
| Oxycodone | drug interactions | Oxycodone (CYP3A4 Inhibition) Significantly Increased Increased visual effects (heterophoria and miosis) of oxycodone were observed when concomitantly administered with VFEND. |
| Phenobarbital | drug interactions | Drug/Drug Class (Mechanism of Interaction by the Drug): Long Acting Barbiturates (e.g., phenobarbital, mephobarbital) (CYP450 Induction); … |
| Phenytoin | drug interactions | Drug/Drug Class (Mechanism of Interaction by the Drug): Phenytoin (CYP450 Induction); Voriconazole Plasma Exposure (C max and AUC τ after 200 mg every 12 hours): Significantly Reduced; … |
| Pimozide | drug interactions | Drug/Drug Class (Mechanism of Interaction by Voriconazole): Pimozide, Quinidine, Ivabradine (CYP3A4 Inhibition); Drug Plasma Exposure (C max and AUC τ): Not Studied In Vivo or In Vitro, but Drug … |
| Prednisolone | drug interactions | Drug/Drug Class (Mechanism of Interaction by Voriconazole): Prednisolone and other corticosteroids (CYP3A4 Inhibition); Drug Plasma Exposure (C max and AUC τ): In Vivo Studies Showed No Significant … |
| Quinidine | drug interactions | Drug/Drug Class (Mechanism of Interaction by Voriconazole): Pimozide, Quinidine, Ivabradine (CYP3A4 Inhibition); Drug Plasma Exposure (C max and AUC τ): Not Studied In Vivo or In Vitro, but Drug … |
| Ribociclib | drug interactions | … cobimetinib, dabrafenib, dasatinib, nilotinib, sunitinib, ibrutinib, ribociclib) (CYP3A4 Inhibition); Drug Plasma Exposure (C max and AUC τ): Not Studied In Vivo or In Vitro, but Drug Plasma Exposure … |
| Rifabutin | contraindications | Rifabutin [see Clinical Pharmacology (12.3) ] |
| Rifampin | drug interactions | Drug/Drug Class (Mechanism of Interaction by the Drug): Rifampin Results based on in vivo clinical studies generally following repeat oral dosing with 200 mg every 12 hours voriconazole to healthy … |
| Ritonavir | contraindications | Ritonavir Concomitant use with high-dose ritonavir (400 mg every 12 hours) is contraindicated. |
| Sirolimus | contraindications | Sirolimus [see Clinical Pharmacology (12.3) ] |
| Sufentanil | drug interactions | Reduction in the dose of alfentanil and other opiates metabolized by CYP3A4 (e.g., sufentanil) should be considered when concomitantly administered with VFEND. |
| Sunitinib | drug interactions | … cabozantinib, ceritinib, cobimetinib, dabrafenib, dasatinib, nilotinib, sunitinib, ibrutinib, ribociclib) (CYP3A4 Inhibition); … |
| Tacrolimus | drug interactions | Drug/Drug Class (Mechanism of Interaction by Voriconazole): Tacrolimus (CYP3A4 Inhibition); Drug Plasma Exposure (C max and AUC τ): Significantly Increased; … |
| Tolvaptan | drug interactions | Drug/Drug Class (Mechanism of Interaction by Voriconazole): Tolvaptan (CYP3A4 Inhibition); Drug Plasma Exposure (C max and AUC τ): Although Not Studied Clinically, Voriconazole is Likely to … |
| Tretinoin | drug interactions | Drug/Drug Class (Mechanism of Interaction by Voriconazole): Tretinoin (CYP3A4 Inhibition); Drug Plasma Exposure (C max and AUC τ): Although Not Studied, Voriconazole may Increase Tretinoin … |
| Triazolam | drug interactions | Drug/Drug Class (Mechanism of Interaction by Voriconazole): Other benzodiazepines including triazolam and alprazolam (CYP3A4 Inhibition); … |
| Venetoclax | drug interactions | Drug/Drug Class (Mechanism of Interaction by Voriconazole): Venetoclax (CYP3A4 Inhibition); Drug Plasma Exposure (C max and AUC τ): Not Studied In Vivo or In Vitro, but Venetoclax Plasma Exposure … |
| Voclosporin | contraindications | Voclosporin 2. |
| Warfarin | drug interactions | Drug/Drug Class (Mechanism of Interaction by Voriconazole): Warfarin (CYP2C9 Inhibition); Drug Plasma Exposure (C max and AUC τ): Prothrombin Time Significantly Increased; … |
Other labels that name voriconazole
- Aficamten
- Alosetron
- Atazanavir
- Atorvastatin
- Cabazitaxel
- Calcifediol
- Cobicistat
- Darunavir
- Dexlansoprazole
- Dienogest and estradiol
- Doxazosin
- Dronedarone
- Drospirenone and estradiol
- Drospirenone and ethinyl estradiol
- Drospirenone and ethinyl estradiol and levomefolate
- Erlotinib
- Esomeprazole
- Ethinyl estradiol and ferrous bisglycinate and levonorgestrel
- Ethinyl estradiol and ferrous fumarate and levonorgestrel
- Ethinyl estradiol and levonorgestrel
- Ethinyl estradiol and norelgestromin
- Ethinyl estradiol and norgestimate
- Ethinyl estradiol and segesterone
- Etonogestrel
- Fluticasone
- Glipizide
- Hydrocortisone
- Irinotecan
- Lansoprazole
- Lovastatin
- Mifepristone
- Nateglinide
- Nimodipine
- Palbociclib
- Paricalcitol
- Rilpivirine
- Simvastatin
- Ticagrelor
- Toremifene
- Trabectedin
- Trastuzumab emtansine
- Trazodone
- Umeclidinium and vilanterol
- Vilazodone
Source: FDA drug label (VFEND), NDA021630 (Pf Prism Cv), as published by Roerig, effective February 26, 2026 (SPL set ce3ef5cf-3087-4d92-9d94-9eb8287228db), via openFDA; the full label on DailyMed
What do FAERS reports show for voriconazole?
The FDA Adverse Event Reporting System holds 30,201 reports that list voriconazole among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 8,851 are coded as a death and 12,143 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as voriconazole?
8 other medicines are given the same way (oral) and in the same FDA class as voriconazole or labeled mainly for the same use (fungal infections), the same class first. Fungal infections lists all 33 medicines labeled for it, by any route. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (oral) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Fluconazole | Fungal infections | 38 labelers | $0.380 per tablet 200 mg tablet | No current entry |
| Posaconazole | Fungal infections | 21 labelers | $2.03 per tablet 100 mg tablet | A presentation being discontinued |
| Itraconazole | Fungal infections | 11 labelers | $0.910 per capsule 100 mg capsule | A presentation being discontinued |
| Clotrimazole | Fungal infections | 3 labelers | $0.292 per troche 10 mg troche | No current entry |
| Terbinafine | Fungal infections | 22 labelers | $0.143 per tablet 250 mg tablet | No current entry |
| Nystatin | Fungal infections | 21 labelers | $0.0569 per mL 100,000 unit/mL suspension | No current entry |
| Griseofulvin | Fungal infections | 10 labelers | $3.74 per tablet 250 mg tablet | No current entry |
| Flucytosine | Fungal infections | 9 labelers | n/a | No current entry |
Every medicine labeled for the same conditions as voriconazole
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
How does voriconazole compare with medicines for the same use?
6 side-by-side pages set voriconazole beside a medicine whose label shares a use: approvals, generics, pharmacy cost, warnings and supply.
What next?
- Alternatives to voriconazole
- 8 medicines for the same use
- Other azole antifungals
- the pharmacologic class, with prices and generics
- Voriconazole side effects
- the label's list beside FAERS reports
- Voriconazole shortage record
- every presentation, company and date
- Check an interaction
- what two or more labels say about each other